Information on vaccines available (at the time of review, October 2022) in the UK and relevant to the HBLB Codes of Practice
|Equip Artervac*||Zoetis||For the active immunisation of horses and ponies against equine arteritis virus (EAV) in order to reduce clinical signs and shedding of virus in bodily secretions after infection.|
|Equip EHV-1,4||Zoetis||For active immunisation of horses to reduce clinical respiratory signs due to infection with EHV-1 and EHV-4 and to reduce abortion caused by EHV-1 infection.|
|Equip F||Zoetis||For active immunisation of horses against EI, to reduce clinical signs and shedding of virus after infection.|
|Equilis Prequenza||MSD Animal Health||For active immunisation of horses against EI, to reduce clinical signs and shedding of virus after infection.|
|Proteq Flu||Boehringer Ingelheim||For active immunisation of horses against EI, to reduce clinical signs and shedding of virus after infection|
|Equilis Strep E||MSD Animal Health||For immunisation of horses against S.equi to reduce clinical signs and occurence of lymph node abscesses. The vaccine is intended for use in horses for which a risk of S.equi infection has been clearly identified, due to contact with horses from areas where this pathogen is known to be present eg stables with horses that travel to shows and/or competitions in such areas, or stables that obtain or have livery horses from such areas.|
Active immunisation of horses and ponies from 5 months of age for:
- Reduction of body temperature increase, coughing, inappetence, difficulty swallowing, and changes in demeanour in the acute stage of infection with Streptococcus equi.
- Reduction of number of abscesses within submandibular and retropharyngeal lymph nodes. (licensed use - taken from
Veterinary advice should be sought on the choice, timing and administration of any vaccine.
*Veterinary surgeons and horse owners should be aware that the current datasheet requirement for the only inactivated EAV vaccine currently licensed for use in Europe (Equip Artervac) is for six monthly boosters and not 12 monthly (annual) boosters as was originally the case for this vaccine. This has been the requirement since April 2005, when the vaccine was granted a full market authorisation by the Veterinary Medicines Directorate (VMD) in the UK. Noncompliance with this booster interval requirement may necessitate investigation of the viral shedding status of stallions by Defra/APHA under the Equine Viral Arteritis Order 1995.
Vaccination is recommended as one means of aiding the prevention of disease. The listing of vaccines above is for information purposes only and does not imply endorsement of the products by the HBLB, its Veterinary Advisory Committee or Sub-Committees. The information given is accurate at the time of printing.